Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIOP Study of Combined Modality Treatment in Childhood Ependymoma
NCT00004224Phase 2Completed
- Sponsor
- SIOP
- Start
- Jan 1999
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label trial of cyclophosphamide, etoposide and vincristine in ependymoma (2 arms), sponsored by SIOP. Primary endpoints: Event-Free Survival, Overall Survival and 2 more. Started Jan 1999; status: completed.
02
Drugs
cyclophosphamideetoposidevincristine
03
Conditions
ependymoma
Beyond the preview
Go deeper on NCT00004224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004224.